An observational study in Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS) and Cortical-basal Ganglionic Degeneration (CBGD), sponsored by University of California, San Francisco. Completed at 8 sites in 2 countries. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by University of California, San Francisco · Observational
Among 37 studies in Corticobasal Degeneration with a site in United States — 13 open to participants now, 17 under way, none of them phase 3. Corticobasal Degeneration · United States.
Among the 37 studies in Corticobasal Degeneration with a site in United States, this one is the 8th largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2016, is one of 19 observational ones, and was the 13th registered.
64 studies on the registry are indexed under Corticobasal Degeneration; 26 are open to participants now.
Browse Corticobasal Degeneration studies →13 of the 37 studies in Corticobasal Degeneration with a site in United States are open now. Recruiting first, the newest first:
Jennifer Whitwell · Sites in United States
Ages 18+ · Healthy volunteers
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
Massachusetts General Hospital · Sites in United States
Ages 35+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 50–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Corticobasal Degeneration studies recruiting now, 12 (57%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 1
First in 2005; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 186 across 35 observational studies indexed under Corticobasal Degeneration.
Median enrollment 73 across the 18 interventional studies, 180 across the 19 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 37 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.
University of California, San Francisco has 6 studies filed under Corticobasal Degeneration — fewer than ten, so there is no comparison to draw.
4 of the studies in Corticobasal Degeneration with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05653778Johns Hopkins UniversityScrambler Therapy for Corticobasal Syndrome-Associated Pain | 2027-02 |
| NCT05073471Johns Hopkins UniversityMusic and Brain Stimulation for Upper Extremity Performance in Patients With Corticobasal Syndrome | 2027-06-30 |
| NCT02994719Beth Israel Deaconess Medical CenterGait Analysis in Neurological Disease | 2027-07-07 |
| NCT03225144National Institute of Neurological Disorders and Stroke (NINDS)Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia | 2027-10-30 |
Among the 37 studies in Corticobasal Degeneration with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
Participants diagnosed with Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy, or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP); Healthy Volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
Other: Observational Study
Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
Other: Observational Study
Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
Other: Observational Study
Tau-PET Brain Scan
Change from Baseline of Tau protein distribution in the brain.
Time frame: Baseline, 1-year, and 2-years.
Amyloid-PET Brain Scan
Presence of Amyloid in the brain at Baseline.
Time frame: Baseline
Brain Volume on MRI
Change from Baseline of brain tissue volume.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Progressive Supranuclear Palsy Rating Scale (PSPRS)
Change from Baseline of this rating scale.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Corticobasal Degeneration Functional Scale (CBDFS)
Change from Baseline of this rating scale.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Eye Movement Function
Change from Baseline of eye movement function.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Retinal Imaging
Change from Baseline of retinal thickness.
Time frame: Baseline, 6-months, 1-year, and 2-years.
UDS Neuropsychological Testing Battery, including supplemental FTLD Module
Change fromm Baseline of cognitive function.
Time frame: Baseline, 6-months, 1-year, and 2-years.
Plan to share: Yes — Deidentified participant data are available by request .
The record gives a start of Jan 2016, a primary completion of Feb 2024 and a completion of Feb 2024. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →